Advertisement
Advertisement

FLNA

F

Filana Therapeutics, Inc. Common Stock

1.02
USD
Sponsored
+0.03
+3.02%
Aug 10, 11:54 UTC -4
Open

Filana Therapeutics, Inc. Common Stock Profile

About

Filana Therapeutics Inc. is a biotechnology company focused on developing novel medicines to modulate the filamin A protein for the treatment of central nervous system disorders, such as Tuberous Sclerosis Complex related epilepsy and other diseases associated with dysregulation or overexpression of filamin A. Filana Therapeutics Inc., formerly known as Cassava Sciences, Inc., is based in AUSTIN, Texas.

Info & Links

CEO

Richard J. Barry

Headquarters

6801 N. CAPITAL OF TEXAS HIGHWAY, BUILDING 1; SUITE 300
AUSTIN, TX 78731, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.filanatx.com

Auditor

Ernst & Young LLP

Share holders

30

Employees

17

Filana Therapeutics, Inc. Common Stock Statistics

Valuation Measures

Market Capitalization2

49.52M

Enterprise Value

-33.17M

Enterprise Value/EBITDA(ttm)

0.74

Price to Earnings Ratio(ttm)

--

Price to Sales(ttm)

--

Price to Book(mrq)

0.76

Price to Cash(ytd)

--

Profitability

Gross Margin(ttm)

0.00%

Operating Margin(ttm)

--

Profit Margin(ttm)

0.00%

Return on Equity(ttm)

-58.78%

Return on Invested Capital(ttm)

-58.79%

Return on Assets(ttm)

-36.74%

Income Statement

Revenue(ttm)

0.00

Revenue Per Share(ttm)

0.00

Gross Profit(ttm)

0.00

EBITDA(ttm)3

-44.99M

Net Income Available to Common(ttm)

-42.28M

Diluted EPS(ttm)

-0.87

Share Statistics

Beta (5Y Monthly)

-0.70

52-Week Change

--

S&P 500 52-Week Change

21.83%

S&P 500 Member

No

Stock Optionable

Yes

Total Shares Outstanding1

48.31M

Dividend Yield

0.00%

Float4

46.09M

% Held by Insiders

4.60%

% Held by Institutions

38.05%

Balance Sheet

Total Cash(mrq)

82.68M

Total Cash Per Share(mrq)

1.71

Total Debt(mrq)

0.00

Total Debt/Equity(mrq)

0.00%

Current Ratio(mrq)

2.08%

Quick Ratio(mrq)

2.08%

Book Value Per Share(mrq)

1.32

Cash Flow

Operating Cash Flow Per Share(ytd)

-0.26

Free Cash Flow(ytd)

-12.75M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement